- Home
- UNCY vs CUE Comparison
UNCY vs CUE Comparison
Compare UNCY & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- CUE
- Stock Information
- Founded
- UNCY 2016
- CUE 2014
- Country
- UNCY United States
- CUE United States
- Employees
- UNCY N/A
- CUE N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- CUE Health Care
- Exchange
- UNCY Nasdaq
- CUE Nasdaq
- Market Cap
- UNCY 56.4M
- CUE 59.5M
- IPO Year
- UNCY 2021
- CUE 2018
- Fundamental
- Price
- UNCY $4.70
- CUE $0.83
- Analyst Decision
- UNCY Strong Buy
- CUE Strong Buy
- Analyst Count
- UNCY 4
- CUE 2
- Target Price
- UNCY $63.75
- CUE $3.00
- AVG Volume (30 Days)
- UNCY 384.1K
- CUE 150.4K
- Earning Date
- UNCY 08-14-2025
- CUE 08-12-2025
- Dividend Yield
- UNCY N/A
- CUE N/A
- EPS Growth
- UNCY N/A
- CUE N/A
- EPS
- UNCY N/A
- CUE N/A
- Revenue
- UNCY N/A
- CUE $8,286,000.00
- Revenue This Year
- UNCY N/A
- CUE N/A
- Revenue Next Year
- UNCY $1,178.98
- CUE $23.84
- P/E Ratio
- UNCY N/A
- CUE N/A
- Revenue Growth
- UNCY N/A
- CUE N/A
- 52 Week Low
- UNCY $2.75
- CUE $0.45
- 52 Week High
- UNCY $11.00
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- UNCY 52.02
- CUE 53.41
- Support Level
- UNCY $3.97
- CUE $0.76
- Resistance Level
- UNCY $4.43
- CUE $0.84
- Average True Range (ATR)
- UNCY 0.25
- CUE 0.08
- MACD
- UNCY 0.10
- CUE -0.00
- Stochastic Oscillator
- UNCY 73.00
- CUE 61.86
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.